MX2012005132A - Composicion, metodo y kit para inhibidor de alfa-1 proteinasa. - Google Patents
Composicion, metodo y kit para inhibidor de alfa-1 proteinasa.Info
- Publication number
- MX2012005132A MX2012005132A MX2012005132A MX2012005132A MX2012005132A MX 2012005132 A MX2012005132 A MX 2012005132A MX 2012005132 A MX2012005132 A MX 2012005132A MX 2012005132 A MX2012005132 A MX 2012005132A MX 2012005132 A MX2012005132 A MX 2012005132A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- kit
- alpha
- proteinase inhibitor
- api
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 title 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25771109P | 2009-11-03 | 2009-11-03 | |
| PCT/US2010/055135 WO2011056793A2 (en) | 2009-11-03 | 2010-11-02 | Composition, method, and kit for alpha-1 proteinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012005132A true MX2012005132A (es) | 2012-07-25 |
Family
ID=43970713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012005132A MX2012005132A (es) | 2009-11-03 | 2010-11-02 | Composicion, metodo y kit para inhibidor de alfa-1 proteinasa. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20130131192A1 (enExample) |
| EP (1) | EP2496246B1 (enExample) |
| JP (2) | JP2013510158A (enExample) |
| KR (1) | KR20120114235A (enExample) |
| CN (1) | CN102655876B (enExample) |
| AU (1) | AU2010315325B2 (enExample) |
| BR (1) | BR112012010392B8 (enExample) |
| CA (1) | CA2779369C (enExample) |
| CL (1) | CL2012001159A1 (enExample) |
| ES (1) | ES2679819T3 (enExample) |
| HU (1) | HUE039240T2 (enExample) |
| IL (1) | IL219485A (enExample) |
| MX (1) | MX2012005132A (enExample) |
| NZ (1) | NZ599783A (enExample) |
| PL (1) | PL2496246T3 (enExample) |
| PT (1) | PT2496246T (enExample) |
| RU (1) | RU2555332C2 (enExample) |
| TR (1) | TR201809898T4 (enExample) |
| WO (1) | WO2011056793A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015504051A (ja) * | 2011-12-30 | 2015-02-05 | グライフォルス・ス・アー | 肺の増悪の発現または進行を遅延させるためのアルファ１−プロテイナーゼ阻害剤 |
| US20210085764A1 (en) * | 2016-12-22 | 2021-03-25 | Kamada Ltd. | Dry powder formulations of alpha-1 antitrypsin |
| WO2018132874A1 (en) * | 2017-01-19 | 2018-07-26 | Csl Limited | Method of preventing an immune response with alpha- 1 anti-trypsin |
| IL267923B2 (en) | 2018-08-02 | 2023-06-01 | Grifols Worldwide Operations Ltd | The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it |
| WO2020180390A1 (en) * | 2019-03-04 | 2020-09-10 | TAE Life Sciences | Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof |
| TW202139973A (zh) | 2020-02-25 | 2021-11-01 | 愛爾蘭商格里佛全球營運有限公司 | 獲得α-1蛋白酶抑制劑的方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5029005B2 (enExample) * | 1972-05-08 | 1975-09-19 | ||
| JPS51118819A (en) * | 1975-04-08 | 1976-10-19 | Green Cross Corp:The | A process for preparing heat stable antitrypsin |
| JPS597693B2 (ja) | 1978-01-07 | 1984-02-20 | 株式会社ミドリ十字 | 抗トロンビン製剤及びその製法 |
| US4337242A (en) | 1980-02-05 | 1982-06-29 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| US4623717A (en) * | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
| EP0082481B2 (en) | 1981-12-23 | 1990-09-12 | Schering Corporation | Stabilised alpha-interferon formulations and their preparation |
| US4517294A (en) | 1982-03-03 | 1985-05-14 | Genentech, Inc. | Human antithrombin III |
| US4632981A (en) | 1982-07-30 | 1986-12-30 | Genentech, Inc. | Human antithrombin III |
| US5218091A (en) | 1982-08-13 | 1993-06-08 | Zymogenetics, Inc. | Glycolytic promoters for regulated protein expression: protease inhibitor |
| US4711848A (en) | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4732973A (en) | 1984-06-14 | 1988-03-22 | Chiron Corporation | Active site modified protease α-1-antitrypsin inhibitors |
| DE3581328D1 (de) | 1984-06-19 | 1991-02-21 | Transgene Sa | Derivate des menschlichen alpha-1-antitrypins und verfahren zu deren herstellung. |
| US5322775A (en) | 1986-06-30 | 1994-06-21 | Pharmaceutical Proteins Ltd. | Peptide production |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| DE3901917A1 (de) | 1989-01-24 | 1990-07-26 | Behringwerke Ag | Mutanten von humanem antithrombin iii |
| GB8913183D0 (en) | 1989-06-08 | 1989-07-26 | Central Blood Lab Authority | Chemical products |
| US5079336A (en) | 1989-06-23 | 1992-01-07 | The Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin, analogues and methods of production |
| US5032405A (en) | 1989-09-27 | 1991-07-16 | Warner-Lambert Company | Oral pharmaceutical composition for acid sensitive proteinaceous agents |
| US5134119A (en) | 1990-10-16 | 1992-07-28 | Lezdey John | Treatment of inflammation using 358 substituted alpha-antitrypsin |
| JP3479539B2 (ja) | 1992-04-10 | 2003-12-15 | エーザイ株式会社 | ヒトアンチトロンビンｉｉｉ変異体 |
| US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| FR2719479B1 (fr) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
| US5561115A (en) | 1994-08-10 | 1996-10-01 | Bayer Corporation | Low temperature albumin fractionation using sodium caprylate as a partitioning agent |
| US5843705A (en) | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| AT407114B (de) | 1997-06-10 | 2000-12-27 | Immuno Ag | Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung |
| CA2328397A1 (en) | 1998-05-12 | 1999-11-18 | Temple University - Of The Commonwealth System Of Higher Education | Human antithrombin iiis and methods related thereto |
| DK2130554T3 (da) | 1999-02-22 | 2012-12-03 | Univ Connecticut | Albuminfrie faktor VIII-præparater |
| US7704958B1 (en) * | 1999-03-05 | 2010-04-27 | Bio Holding, Inc. | Methods and compositions for inhibiting apoptosis using serine protease inhibitors |
| US20040157911A1 (en) | 1999-08-31 | 2004-08-12 | Spiridon Spireas | Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof |
| DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US20030170813A1 (en) | 2000-07-05 | 2003-09-11 | Kenichi Suga | Process for producing glycoprotein |
| AU2002335046A1 (en) * | 2001-10-19 | 2003-05-06 | Inhale Therapeutic Systems, Inc. | The use of proton sequestering agents in drug formulations |
| US20030235555A1 (en) | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| EP1558273B1 (en) * | 2002-04-25 | 2011-08-17 | The Scripps Research Institute | Treatment and prevention of pulmonary conditions |
| US7777006B2 (en) * | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
| DE602004013021T3 (de) | 2003-09-22 | 2012-04-05 | Kamada Ltd. | Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung |
| US7691810B2 (en) | 2003-10-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Method of producing recombinant antithrombin III composition |
| ATE530165T1 (de) | 2003-11-14 | 2011-11-15 | Baxter Int | Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen |
| WO2005049801A2 (en) | 2003-11-14 | 2005-06-02 | Arriva Pharmaceuticals, Inc. | Dry protein formulation |
| US20050226893A1 (en) | 2004-03-04 | 2005-10-13 | Jennifer Juneau | Lyophilization method to improve excipient crystallization |
| US20070105768A1 (en) * | 2004-11-10 | 2007-05-10 | Rajiv Nayar | Dry recombinant human alpha 1-antitrypsin formulation |
| WO2007062040A1 (en) | 2005-11-22 | 2007-05-31 | Wyeth | Immunoglobulin fusion protein formulations |
| PT1981572E (pt) | 2006-02-09 | 2013-02-26 | Pari Pharma Gmbh | Distribuição pulmonar de inibidor de alfa-i proteinase |
| PL2503995T3 (pl) | 2009-11-24 | 2018-01-31 | Grifols Therapeutics Inc | Sposoby liofilizacji, kompozycje i zestawy |
-
2010
- 2010-11-02 AU AU2010315325A patent/AU2010315325B2/en active Active
- 2010-11-02 MX MX2012005132A patent/MX2012005132A/es active IP Right Grant
- 2010-11-02 CA CA2779369A patent/CA2779369C/en active Active
- 2010-11-02 RU RU2012122793/15A patent/RU2555332C2/ru active
- 2010-11-02 PL PL10828979T patent/PL2496246T3/pl unknown
- 2010-11-02 ES ES10828979.4T patent/ES2679819T3/es active Active
- 2010-11-02 EP EP10828979.4A patent/EP2496246B1/en not_active Revoked
- 2010-11-02 BR BR112012010392A patent/BR112012010392B8/pt active IP Right Grant
- 2010-11-02 JP JP2012537945A patent/JP2013510158A/ja not_active Withdrawn
- 2010-11-02 CN CN201080054535.7A patent/CN102655876B/zh active Active
- 2010-11-02 KR KR1020127013706A patent/KR20120114235A/ko not_active Ceased
- 2010-11-02 NZ NZ599783A patent/NZ599783A/xx unknown
- 2010-11-02 WO PCT/US2010/055135 patent/WO2011056793A2/en not_active Ceased
- 2010-11-02 HU HUE10828979A patent/HUE039240T2/hu unknown
- 2010-11-02 PT PT108289794T patent/PT2496246T/pt unknown
- 2010-11-02 TR TR2018/09898T patent/TR201809898T4/tr unknown
- 2010-11-02 US US13/504,783 patent/US20130131192A1/en not_active Abandoned
-
2012
- 2012-04-30 IL IL219485A patent/IL219485A/en active IP Right Grant
- 2012-05-03 CL CL2012001159A patent/CL2012001159A1/es unknown
-
2015
- 2015-09-04 JP JP2015175001A patent/JP6030201B2/ja active Active
- 2015-10-29 US US14/926,450 patent/US9616126B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY160893A (en) | Acid-soluble cement compositions comprising cement kiln dust and/or a natural pozzolan and method of use | |
| WO2007141736A3 (en) | Enzyme stabilization | |
| WO2009125401A3 (en) | Compositions and methods for enhancing oil content in plants | |
| EP3730595A3 (en) | Cleaning composition comprising amylase variants with high stability in the presence of a chelating agent | |
| ZA200903305B (en) | Concentrated Surfactant Compositions | |
| MX2012005132A (es) | Composicion, metodo y kit para inhibidor de alfa-1 proteinasa. | |
| MY160040A (en) | Synthetic bile acid composition, method and preparation | |
| PL2092037T3 (pl) | Kompozycje do stosowania jako czynnik chłodniczy | |
| WO2011113798A3 (en) | Inhibitors of semicarabazide - sensitive amine oxidase | |
| MX2009003600A (es) | Composiciones que tienen un compartimiento indicador. | |
| WO2010055160A3 (de) | Saure wässrige thiodiglykolethoxlat zusammensetzung und ihre verwendung in einem beizverfahren von metallischen oberflächen | |
| MX2010004911A (es) | Metodo de limpieza con acido en la industria cervecera. | |
| WO2009137778A3 (en) | Methods and compositions for genetically engineering clostridia species | |
| MX2009012170A (es) | Tinte de concreto basado en acido debil. | |
| EA200970164A1 (ru) | Ингибиторы каспазы на основе пиридазинонового каркаса | |
| PH12012501184A1 (en) | Nutritional compositions comprising fruit flakes containing docosahexaenoic acid | |
| IL209296A0 (en) | Proton pump inhibitor containing compositions and uses thereof | |
| WO2010039763A3 (en) | Compositions for use in identification of antibiotic-resistant bacteria | |
| TW200619875A (en) | Compositions comprising tannic acid as corrosion inhibitor | |
| WO2009093262A3 (en) | Process for preparing aromatase inhibitor exemestane | |
| WO2010132852A3 (en) | Protease inhibitors | |
| WO2012087434A3 (en) | Use of phosphoric acid for treating cardiovascular disorders | |
| WO2010122426A3 (en) | Methods and compositions for visualization of fluorescent proteins | |
| WO2010075060A3 (en) | Methods and compositions for modulating proline levels | |
| WO2013022746A3 (en) | Composition containing a polysaccharide hybrid polymer and methods of controlling hard water scale |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |